Atea targets mid-2026 Phase III HCV results while expanding hepatitis pipeline and maintaining $329.3M cash runway

Q3 2025 Management View CEO Jean-Pierre Sommadossi reported "significant progress and achievements" this quarter, highlighting the advancement of Atea's global Phase III program for HCV. He stated ...
TipRanks on MSN

Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism

Atea Pharmaceuticals, Inc. (($AVIR)) has held its Q3 earnings call. Read on for the main highlights of the call. Atea Pharmaceuticals’ recent ...
Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global C…

The Hepatitis B and C Therapeutics Market has entered a renewed growth cycle in 2024, led by innovative antiviral regimens, ...
Nasdaq

Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...